Literature DB >> 16580941

Fetal effects of primary and secondary cytomegalovirus infection in pregnancy.

Asher Ornoy1, Orna Diav-Citrin.   

Abstract

Seroconversion to cytomegalovirus (CMV) occurs in 1-4% of pregnant women. The majority of these women are seropositive prior to pregnancy. In 0.2-2.5% of the newborn infants, there is evidence of intrauterine infection, most of them are born without any clinical findings. The typical clinical symptoms of congenital CMV (symptomatic congenital CMV) that are found in 10-20% of infected neonates include intrauterine growth restriction (IUGR), microcephaly, hepatosplenomegaly, petechiae, jaundice, chorioretinitis, thrombocytopenia, anemia and/or other atypical findings. Of special problem are the different neurodevelopmental sequelae such as mental retardation, motor impairment, sensorineural hearing loss or visual impairment, which may occur even in infants who are free of symptoms at birth. Most infants born with severe neonatal symptoms of congenital CMV are born to mothers with primary infection in pregnancy. However, since over 60% of the infants infected in utero with CMV are born to mothers with preconceptional immunity who have secondary infection in pregnancy, and more and more studies show severe sequelae in these infants, we have to conclude that congenital CMV may be a significant problem even in children born to mothers with pre-pregnancy immunization. This may justify the use of invasive methods for the detection of possible fetal infection even in cases of secondary CMV infection. This also brings in an additional problem, when considering the need for proper immunization against CMV, as immunization is primarily aimed for women without immunity.

Entities:  

Mesh:

Year:  2006        PMID: 16580941     DOI: 10.1016/j.reprotox.2005.02.002

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  45 in total

Review 1.  Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway.

Authors:  E Carla Parker-Athill; Jun Tan
Journal:  Neurosignals       Date:  2010-10-02

Review 2.  Public health and laboratory considerations regarding newborn screening for congenital cytomegalovirus.

Authors:  Sheila C Dollard; Mark R Schleiss; Scott D Grosse
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

3.  Cytomegalovirus may mimic the presentation of intrahepatic cholestasis and hemolysis, elevated liver enzymes and low platelets in immunosuppressed pregnant women.

Authors:  Gurleen Wander; Francesa Neuberger; Mandish K Dhanjal; Catherine Nelson-Piercy; May Ching Soh
Journal:  Obstet Med       Date:  2016-05-05

4.  Shedding of Epstein-Barr virus and cytomegalovirus from the genital tract of women in a periurban community in Andhra Pradesh, India.

Authors:  Michelle I Silver; Proma Paul; Pavani Sowjanya; Gayatri Ramakrishna; Haripriya Vedantham; Basany Kalpana; Keerti V Shah; Patti E Gravitt
Journal:  J Clin Microbiol       Date:  2011-04-27       Impact factor: 5.948

5.  Proteomic and phylogenetic coevolution analyses of pM79 and pM92 identify interactions with RNA polymerase II and delineate the murine cytomegalovirus late transcription complex.

Authors:  Travis J Chapa; Yushen Du; Ren Sun; Dong Yu; Anthony R French
Journal:  J Gen Virol       Date:  2017-02-12       Impact factor: 3.891

6.  Establishment of rat brain endothelial cells susceptible to rat cytomegalovirus ALL-03 infection.

Authors:  Siti-Nazrina Camalxaman; Nazariah Allaudin Zeenathul; Yi-Wan Quah; Hwei-San Loh; Hassan Zuridah; Homayoun Hani; Abdul Rahman Sheikh-Omar; Mohd Lila Mohd-Azmi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-02-22       Impact factor: 2.416

Review 7.  Viral infections during pregnancy.

Authors:  Michelle Silasi; Ingrid Cardenas; Ja-Young Kwon; Karen Racicot; Paula Aldo; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2015-01-13       Impact factor: 3.886

8.  Clinical and radiologic evaluation of cytomegalovirus-induced thrombocytopenia in infants between 1 and 6 months of age.

Authors:  Joon-Won Kang; Gee-Na Kim; Sun-Young Kim; Hee-Jin Kim; Eun-Sil Park; Jae-Young Kim; Young-Ho Lee
Journal:  Korean J Hematol       Date:  2010-03-31

9.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09

10.  A pilot study using residual newborn dried blood spots to assess the potential role of cytomegalovirus and Toxoplasma gondii in the etiology of congenital hydrocephalus.

Authors:  Regina M Simeone; Sonja A Rasmussen; Joanne V Mei; Sheila C Dollard; Jaime L Frias; Gary M Shaw; Mark A Canfield; Robert E Meyer; Jeffrey L Jones; Fred Lorey; Margaret A Honein
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.